Clinical trial
Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous…
NCT00447057 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00447057 |
|---|---|
| Title | Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. |
| Intervention type | Drug |
| Interventions | Pemetrexed, Erlotinib |
| Enrollment | 204 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Mar 13, 2007 |
| Last update posted | Oct 13, 2011 |
| Countries | Austria, Germany, Hungary, Spain, Sweden |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: